Total amount: € 0,00
HOW TO ORDER
A Journal on Angiology
Official Journal of the , the International Union of Phlebology and the
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899
International Angiology 2003 December;22(4):344-8
Autologous transplantation of peripheral blood endothelial progenitor cells (CD34+) for therapeutic angiogenesis in patients with critical limb ischemia
Kudo F. A. 1, Nishibe T. 1,2, Nishibe M. 3, Yasuda K. 1
1 Department of Cardiovascular Surgery, Hokkaido University School of Medicine, Sapporo, Japan
2 Department of Surgery, Division of Thoracic and Cardiovascular Surgery, Fujita Health University, Toyoake, Japan
3 Department of Surgery, Eniwa Midorino Clinic, Eniwa, Japan
Aim. Intramuscular injection of endothelial progenitor cells (EPCs) may constitute an alternative treatment strategy for patients with critical limb ischemia (CLI). We performed transplantations of EPCs (CD34+) extracted from peripheral blood in patients with CLI. The objective of this report is to present the method and early results of intramuscular autologous peripheral blood CD34+ cell transplantation in the ischemic limb.
Methods. CD34+ cell transplantation was performed in 2 limbs of 2 patients with CLI, in cases in which it was not possible to perform surgical or percutaneous revascularization. The patients received a granulocyte colony-stimulating factor (G-CSF) prior to the treatment. CD34+ cells were retrieved from peripheral blood and injected directly into the muscle of the ischemic limb.
Results. CD34+ cells retrieved in patient 1 were 1×105/ml and in patient 2 were 1.6×105/ml. Transcutaneous oxygen pressure in the foot increased and clinical symptoms improved. Newly visible collateral blood vessels were directly documented by angiography.
Conclusion. Satisfactory clinical improvement was achieved by using peripheral blood EPCs (CD34+) in the patients with CLI. No complications arose following the intramuscular administration of peripheral blood CD34+ cells.